Krill harvesting: Aker BioMarine to build new support vessel in China
18 Oct 2018 --- Aker BioMarine is set to build its newest support vessel in China. After signing a memorandum of understanding with representatives from the China Overseas Development Association (CODA), Matts Johansen, CEO of Aker BioMarine noted: “This is the beginning of a unique collaboration bringing together innovative technologies and high-tech competencies from both Norwegian and Chinese companies.”
Replacing their existing transportation vessel La Manche, Aker BioMarine’s new krill support vessel will be based on the latest energy saving and environmentally-friendly technologies. It is hoped that the project will be completed by December 2020.
Designed specifically to meet the unique demands of krill harvesting operations in the challenging Antarctic conditions, the new vessel will feature an integrated cargo handling system. Powered by the latest technology including combustion engines, the vessel will be propelled with an efficient propulsion line with a variable propeller. The supply vessel will be equipped with an advanced heat recovery system helping to reduce the carbon footprint even further.
“Renowned for their expertise and capacity to deliver, we are thrilled to continue modernizing and improving our operations with Chinese partners. This is the beginning of a unique collaboration targeting the delivery of a custom-made Chinese built vessel equipped with truly unique Norwegian technologies,” says Johansen.
“We are delighted to see the continuous deepening relations between China and Norway, providing win-win solutions and mutual benefits. Aker BioMarine’s wish to build a state-of-the-art transport vessel in China embodies this spirit of cooperation between the two nations. We are pleased to be a part of supporting this process and desired to contribute to this cooperation,” says Mr. Hu Weiping, Chairman of CODA.
Earlier this year, Aker BioMarine and Chinese krill harvesting companies together with other members of the Association of Responsible Krill harvesting companies (ARK), came together to adopt voluntary measures to further secure the sustainability of krill harvesting in the Antarctic Ocean.
In further Aker BioMarine news, the company and Lupus Research Alliance have partnered to launch a new clinical study investigating how phospholipid-rich krill oil can benefit people with lupus, with the aim of lessening the severity of symptoms associated with the disease.
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.
COMPANY DETAILS
Oksenøyvn. 10 (Bygg B)
1366 Lysaker
Norway
www.akerbiomarine.com
superba@akerbiomarine.com
Tel: +47 24 13 00 10ACTIVE CATEGORIES
Nutraceutical And Functional Food IngredientsAker BioMarine is a vertically integrated biotechnology company and the world’s leading supplier of krill-derived biotech products. The company is supplying krill marine ingredients through an optimized value chain from raw materials to customer.
Aker BioMarine utilizes its unique krill harvesting methods to develop its own downstream operations within the high value added nutraceutical and aquaculture feed markets.
Krill derived products, such as krill oil and meal, have a high content of bioactive ingredients, e.g. Omega-3 bound phospholipids, choline and astaxanthin, which have documented positive effects on both humans and animals.
Superba KrillTM is the company’s krill oil nutraceutical line for humans and QrillTM covers all krill meal products for both the aquaculture and pet food markets.
Superba Krill is the world’s most researched krill oil brand. The naturally occurring nutrients in krill oil offer many benefits supporting the heart, liver, brain, skin and joints, allowing for optimal end product differentiation by brand owners.
Aker BioMarine has a wide set of capabilities within nutraceuticals (dietary supplements and functional foods) and is an experienced player in nutraceutical applications of lipids, product development, and intellectual property rights (IPR), R&D and product commercialization.
